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SUMMARY – Waldenström’s macroglobulinemia is a distinct clinicopathologic entity defined 
as a B-cell neoplasm characterized by lymphoplasmacytic infiltrate in the bone marrow, with an 
associated immunoglobulin (Ig) M paraprotein. Clinical manifestations are due to deposition of 
IgM in the liver, spleen, and/or lymph nodes, so it presents with anemia, hyperviscosity, lymphade-
nopathy, hepatomegaly, splenomegaly and neurologic symptoms. The main diagnostic criteria are a 
typical peak on serum protein electrophoresis and malignant cells in bone marrow biopsy samples. 
There is no standard therapy for the treatment of symptomatic Waldenström’s macroglobulinemia 
and no agents have been specifically approved for this disease, but initial treatment usually starts 
with the monoclonal anti-CD20 antibody  rituximab, either alone or in combination with other 
agents, rather than chemotherapy alone. This article confirms that, despite the existence of more 
modern imaging methods, ultrasonography still has a significant diagnostic role.
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Introduction
Waldenström’s macroglobulinemia is a rare ma-
lignant monoclonal gammopathy characterized by 
the production of excess IgM monoclonal protein. 
It presents with symptoms related to the infiltration 
of the hematopoietic tissues or the effects of mono-
clonal IgM in the blood. No definite etiology exists 
for Waldenström’s macroglobulinemia, but environ-
mental, familial, genetic, and viral factors have been 
reported. We present a case of a patient who was diag-
nosed with a solitary liver lesion by abdominal ultra-
sonography (US) and had undergone further diagnos-
tic imaging test, and later blood test and biopsy until 
the diagnosis of Waldenström’s macroglobulinemia 
was set1-3.
Case Report
A 61-year-old female patient first presented to our 
department in May 2011 with a history of nonspe-
cific symptoms of weakness, sweating, weight loss, 
and pain in the upper abdomen. Blood tests revealed 
mild anemia, elevated erythrocyte sedimentation 
rate, normal liver function tests, and abdominal US 
showed a hypoechoic lesion measuring 12x8 cm in 
the right liver lobe without change of the US struc-
ture (Fig.1 a, b). The patient underwent further di-
agnostic tests that eliminated infectious, autoimmune 
and systemic causes of the liver lesion. Besides liver 
lesion, computed tomography (CT) showed a couple 
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of enlarged lymph nodes retrocrurally (Fig. 2), but 
the etiology of liver lesion remained unknown, pos-
sible liver steatosis. Then, magnetic resonance imag-
ing (MRI) was performed, indicating that the lesion 
could be due to perfusion problems (Fig. 3). Because 
of the unsolved etiology, the patient was admitted to 
the hospital in September 2011. In the hospital, the 
patient underwent US-guided cytologic biopsy of the 
liver lesion and serum protein electrophoresis was also 
performed. According to the cytology report, abun-
dant smears showed a monotonous picture of numer-
ous lymphoplasmacytes with frequent proplasma and 
plasma cells and some mastocytes, concluding that 
the finding was compatible with the diagnosis of non-
Hodgkin’s lymphoma of the lymphoplasmacytic type. 
Serum protein electrophoresis results were as follows: 
total protein 101 g/L, albumin 27.9 g/L, alpha1-glob-
ulin 2.7 g/L, alpha2-globulin 6.2 g/L, beta-globulin 
54.7 g/L, gamma-globulin 8.5 g/L, M-protein 47.2 
g/L, IgG 4.6, IgA 0.90, IgM 66.8. Bone marrow as-
piration biopsy was also performed to demonstrate a 
lymphoproliferative process with 25% of lymphocytes 
and 2% of plasma cells. In the blood smear, lympho-
cytes accounted for 46% of cells and there were 7% 
of plasma cells. Red blood cells adhered together in 
the rouleau formations due to the high blood protein 
Fig. 1. Abdominal ultrasound showing; A) a hypoechoic lesion 12x8 cm in the right liver lobe; B) without change of 
ultrasound  structure.
1.B1.A
Fig. 2. Computed tomography of the abdomen 70 seconds 
after intravenous contrast aplication. Transverse recon-
struction - centrohilar expansive hypodense liver change.
Fig. 3. Nuclear magnetic resonance, 2-weighted image: 
transverse layers showing centrohilar expansive liver le-
sion.
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content (Fig. 4). Then, the diagnosis of Waldenström’s 
macroglobulinemia was set. 
Chest CT excluded lymphoplasmacytoma sites in 
other solid organs.
Therapy with fludarabine was administered, with 
good patient response. She was released for home care 
in good condition and planned for the next cycle of 
chemotherapy in four weeks. However, she was re-
admitted earlier, through emergency unit because 
of epistaxis, retinal bleeding, and worsening of her 
general condition. Two plasmapheresis sessions were 
done as well as albumin correction, and she received 
crystalloid solutions, three doses of fresh frozen plas-
ma and three doses of irradiated red blood cell con-
centrates. With these interventions, her condition 
improved with serum protein reduction from 83 g/L 
to 75 g/L, and M-peak reduction from 47 g/L to 28.4 
g/L. She also underwent the second cycle of chemo-
therapy with fludarabine and rituximab, and was dis-
charged for home care in good condition.
Discussion
Waldenström’s macroglobulinemia is a rare disease 
with an incidence of approximately three per million 
people per year in the United States and the median 
age at diagnosis is 64 years4. Although it is consid-
ered to be a sporadic disease, familial predisposition is 
present in up to 20 percent of the cases5. 
The disease presents itself with diversity of symp-
toms, which are attributable to tumor infiltration of 
lymphoid tissues and bone marrow, circulating IgM, 
IgM tissue deposition and autoantibody activity of 
IgM. Most patients with Waldenström’s macro-
globulinemia present with nonspecific constitutional 
symptoms like weakness, fatigue, weight loss, but 
also hepatomegaly, splenomegaly, lymphadenopathy, 
bleeding, and symptoms due to hyperviscosity such 
as blurring or loss of vision, headache, vertigo, nys-
tagmus, tinnitus, diplopia or ataxia6,7. Besides clinical 
presentation, reaching the diagnosis of this condition 
requires a number of tests. 
Anemia is found in about 40% of cases, and other 
common findings are lymphocytosis and monocyto-
sis. However, the key criteria are the presence of an 
IgM monoclonal paraprotein on serum protein elec-
trophoresis and 10% or more of the bone marrow bi-
opsy samples showing infiltration by small lympho-
cytes with plasmacytoid or plasma cell differentiation. 
This infiltrate should express a typical immunophe-
notype (e.g., surface IgM+, CD5+/-, CD10-, CD19+, 
CD20+, CD22+, CD23-, CD25+, CD27+, FMC7+, 
CD103-, CD138-)8.
Imaging methods like US, CT and MRI are also 
very important, mostly to evaluate the extension of the 
disease, or as in our case, to set suspicion of the dis-
ease. Focal liver lesions are often detected on routine 
US, but sometimes, as in the case we report, require 
extensive investigations for an accurate diagnosis. 
Differential diagnosis of an US detected hypoechoic 
liver lesion is variable, from liver steatosis either in 
terms of alcoholic or non alcoholic fatty liver disease, 
to benign tumors or malignant primary or metastatic 
liver tumors9. The treatment of Waldenström’s macro-
globulinemia is complex. The decision on whether or 
not to start treatment is based on the patient’s clinical 
condition. For patients with minimal symptoms, the 
treatment of first choice is rituximab because of its low 
toxicity and good response rates. The combination of 
rituximab and chemotherapy is a preferred treatment 
option for patients with severe symptoms related to 
Waldenström’s macroglobulinemia. For the hypervis-
cosity syndrome, the only treatment option is removal 
Fig. 4. Peripheral blood smear: MGG staining, magnifi-
cation x1000: one proplasma and one plasma cell in pe-
ripheral blood. Erythrocytes are sticked together in rouleax 
formations due to high protein content in the blood.
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of IgM from the circulation via plasmapheresis. There 
are also some new agents that are still under study, 
e.g., perifosine, alemtuzumab, imatinib mesylate, 
everolimus, and sildenafil10-12. 
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Sažetak
WALDENSTRÖMOVA MAKROGLOBULINEMIJA KAO DIJAGNOSTIČKI PROBLEM: CASE REPORT
I. Budimir, M. Nikolić, M. Sabol Pušić, D. Hrabar, N. Ljubičić, M. Duvnjak, V. Supanc, I. Nikolac, N. Babić i M. Šokčević
Waldenströmova makroglobulinemija je specifičan kliničkopatološki entitet definiran kao B-stanična neoplazma obi-
lježena limfoplazmatskim infiltratima u koštanoj srži udruženim s paraproteinom imunoglobulinom (Ig) M. Kliničke 
manifestacije nastaju kao posljedica taloženja IgM u jetri, slezeni i/ili limfnim čvorovima, tako da se bolest manifestira 
anemijom, hiperviskozitetom, limfadenopatijom, hepatomegalijom, splenomegalijom i neurološkim simptomima. Glavni 
dijagnostički kriteriji su tipični vršak u elektroforezi serumskih proteina te maligne stanice u uzorcima biopsije koštane 
srži. Ne postoji standardna terapija za liječenje simptomatske Waldenströmove makroglobulinemije i nema lijekova speci-
fično odobrenih za ovu bolest, no liječenje najčešće ne započinje kemoterapijom, nego monoklonskim anti-CD 20 antitije-
lom rituksimabom kao monoterapijom ili u kombinaciji s drugim lijekovima. Ovaj članak potvrđuje da unatoč postojanju 
modernih metoda prikazivanja ultrazvuk i dalje ima značajnu dijagnostičku ulogu.
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